Abstract
In a cohort of 1,047 human immunodeficiency virus type 1-infected patients started on protease inhibitors (PIs), the incidence of severe hepatic cytolysis (alanine aminotransferase concentration five times or more above the upper limit of the normal level >/= 5N) was 5% patient-years after a mean follow-up of 5 months. Only positivity for hepatitis C virus antibodies (hazard ratio [HR], 7. 95; P < 10(-3)) or hepatitis B virus surface antigen (HR, 6.67; P < 10(-3)) was associated with severe cytolysis. Before starting patients on PIs, assessment of liver enzyme levels and viral coinfections is necessary.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
AIDS-Related Opportunistic Infections / immunology
-
AIDS-Related Opportunistic Infections / pathology*
-
Adult
-
Alanine Transaminase / metabolism
-
Female
-
HIV Infections / complications
-
HIV Infections / drug therapy*
-
HIV Infections / immunology
-
HIV Infections / pathology
-
HIV Protease Inhibitors / adverse effects
-
HIV Protease Inhibitors / therapeutic use*
-
HIV-1 / immunology
-
Hepacivirus / immunology
-
Hepatitis B / etiology
-
Hepatitis B / immunology
-
Hepatitis B / pathology*
-
Hepatitis B / virology
-
Hepatitis B virus / immunology
-
Hepatitis C / etiology
-
Hepatitis C / immunology
-
Hepatitis C / pathology*
-
Hepatitis C / virology
-
Hepatocytes / drug effects
-
Hepatocytes / pathology*
-
Hepatocytes / virology
-
Humans
-
Liver / pathology*
-
Male
-
Risk Factors
Substances
-
HIV Protease Inhibitors
-
Alanine Transaminase